CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA216386 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA216386.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ZAVZPRET (ZAVEGEPANT) — Type 1 - New Molecular Entity

Policy FDA-NDA216386 · Neurology

High

Zavzpret (zavegepant) was approved by the FDA on March 9, 2023, as a nasal spray for migraine treatment, billing under Medicare Part D as a self-administered drug. As a nasal spray administered outsid

View alert

Audit documentation

Building an audit file that includes FDA-NDA216386?

The Tripwire Audit Pack exports 12 months of Neurology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Neurology audit pack — $349One-time purchase · not a subscription